Yahoo
Taiwan - Delayed Quote TWD

Bora Pharmaceuticals Co., Ltd. (6472.TW)

365.50 -13.50 (-3.56%)
At close: 1:30:17 PM GMT+8
Chart Range Bar
Loading chart for 6472.TW
  • Previous Close 379.00
  • Open 376.00
  • Bid 365.00 x --
  • Ask 366.00 x --
  • Day's Range 364.00 - 379.50
  • 52 Week Range 330.50 - 651.00
  • Volume 777,168
  • Avg. Volume 740,079
  • Market Cap (intraday) 46.625B
  • Beta (5Y Monthly) 0.46
  • PE Ratio (TTM) 25.70
  • EPS (TTM) 14.22
  • Earnings Date (est.) --
  • Forward Dividend & Yield 10.00 (2.64%)
  • Ex-Dividend Date Jul 31, 2026
  • 1y Target Est 578.90

Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products. In addition, it provides Western pharmaceuticals, including central nervous system medications, antibiotics, and gastrointestinal medications; and nutritional and vitamin supplements, physical recovery, and health care products. The company sells its products directly to clinics, pharmacies, pharmacy chains, and drug stores, as well as through distributors to medical centers, corporate and public hospitals, and regional and district hospitals. Bora Pharmaceuticals Co., LTD. was incorporated in 2007 and is based in Taipei City, Taiwan.

www.bora-corp.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6472.TW
23.10%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
55.09%

1-Year Return

6472.TW
39.57%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
59.10%

3-Year Return

6472.TW
27.84%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
173.95%

5-Year Return

6472.TW
219.13%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
163.21%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 4B
Earnings 25.84M
Profit Margin 0.65%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
1B
2B
3B
4B
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%

Analyst Insights

View More

Analyst Price Targets

480.00
578.90 Average
365.50 Current
729.29 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.91%

  • Return on Assets (ttm)

    4.01%

  • Return on Equity (ttm)

    12.05%

  • Revenue (ttm)

    19.56B

  • Net Income Avi to Common (ttm)

    1.82B

  • Diluted EPS (ttm)

    14.22

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.49B

  • Total Debt/Equity (mrq)

    124.41%

  • Levered Free Cash Flow (ttm)

    1.57B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: